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Background: We analyzed data retrieved through a PubMed search of randomized, placebo-
controlled trials of first-generation antipsychotic long-acting injectables (haloperidol decanoate, 
bromperidol decanoate, and fluphenazine decanoate), and a company database of paliperidone 
palmitate, to compare the benefit-risk ratio in patients with schizophrenia.
Methods: From the eight studies that met our selection criteria, two efficacy and six safety 
parameters were selected for calculation of number needed to treat (NNT), number needed to 
harm (NNH), and the likelihood of being helped or harmed (LHH) using comparisons of active 
drug relative to placebo. NNTs for prevention of relapse ranged from 2 to 5 for paliperidone 
palmitate, haloperidol decanoate, and fluphenazine decanoate, indicating a moderate to large 
effect size.
Results: Among the selected maintenance studies, NNH varied considerably, but indicated 
a lower likelihood of encountering extrapyramidal side effects, such as akathisia, tremor, 
and tardive dyskinesia, with paliperidone palmitate versus placebo than with first-generation 
antipsychotic depot agents versus placebo. This was further supported by an overall higher 
NNH for paliperidone palmitate versus placebo with respect to anticholinergic use and Abnor-
mal Involuntary Movement Scale positive score. LHH for preventing relapse versus use of 
anticholinergics was 15 for paliperidone palmitate and 3 for fluphenazine decanoate, favoring 
paliperidone palmitate.
Conclusion: Overall, paliperidone palmitate had a similar NNT and a more favorable NNH 
compared with the first-generation long-acting injectables assessed.
Keywords: long-acting injectables, first-generation antipsychotics, randomized, number needed 
to treat, number needed to harm, paliperidone palmitate, second-generation antipsychotics
Introduction
Long-acting injectable preparations of both first- and second-generation antipsychotics 
offer certain advantages over oral preparations, such as a longer interval between dos-
ing, the opportunity for the health care provider to intervene if an injection is missed, 
mitigation against the nonadherence or partial adherence that is prevalent with oral 
agents, and the ability to maintain efficacy with improved tolerability, as a result of 
less peak-to-trough fluctuation in plasma concentration.1,2 However, the incidence of 
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has been reported to be considerable with first-generation 
antipsychotic long-acting injectables.3
By comparison, use of second-generation oral and long-
acting injectable antipsychotics have been generally associated 
with a reduced risk of developing tardive dyskinesia and 
treatment-limiting extrapyramidal symptoms.4,5 However, 
there are no randomized controlled trials directly comparing the 
efficacy, safety, and tolerability of first- and second-generation 
long-acting injectables in patients with schizophrenia. In the 
absence of head-to-head comparisons in clinical studies, 
standardized measures of benefit and risk allow practicing 
clinicians to compare clinically discernable treatment effects 
and assess their significance across clinical trials.6
The number needed to treat (NNT), number needed to 
harm (NNH), and likelihood of being helped or harmed 
(LHH) are evidence-based tools that provide information 
on the relative risk or benefit of various treatments.7,8 These 
measures are based on a calculation of the number of patients 
who will likely need to be treated with the test agent to either 
benefit a single patient (NNT) or cause a single patient to 
experience harm (NNH) relative to treatment with the refer-
ence agent (eg, placebo). LHH is the ratio of the absolute 
risk reduction for prevention of an adverse outcome (1/NNT) 
versus an absolute risk increase for safety (1/NNH),9 and 
allows physicians to compare treatments across studies and 
individualize treatment decisions for patients with a distinct 
set of risk factors.9 Thus, NNT, NNH, and LHH provide 
easily translatable information to the health care provider 
and patients.10,11
Here, we report the NNT, NNH, and LHH for selected effi-
cacy and safety parameters from randomized,   placebo-controlled 
studies of paliperidone palmitate, a   second-generation long-
acting injectable antipsychotic, and haloperidol decanoate, 
fluphenazine decanoate, and bromperidol decanoate, three 
first-generation long-acting injectable antipsychotics used 
in patients with schizophrenia. Bromperidol decanoate is an 
older depot neuroleptic used in several European countries. 
The primary objective of this analysis was to compare the 
efficacy and safety of paliperidone palmitate with that of first-
generation long-acting injectable antipsychotics by calculating 
and comparing NNT and NNH based on available data from 
the published literature.
Methods
search criteria
A computerized search of medical literature databases 
was  conducted  in  September  2009  using  PubMed 
(www.pubmed.gov) and an internal company product-related 
database of published abstracts, posters, and articles. 
The literature search was restricted to randomized, controlled 
studies (of any duration, in any language, retrievable through 
PubMed) of known first-generation long-acting injectable 
antipsychotics.
During the PubMed search, the following search terms 
(medical subject headings [MeSH] or verbatim) were used to 
encompass all known first-generation long-acting injectable 
antipsychotics, ie, fluphenazine decanoate, haloperidol 
decanoate, bromperidol decanoate, clopenthixol decanoate, 
flupenthixol decanoate, pipothiazine palmitate, fluspirilene, 
and perphenazine enanthate. For these MeSH terms, the field 
tags were limited to “title or abstract”. In addition, “type 
of article” was limited to “randomized controlled trial”, 
“human” was selected for “species”, the “age” criterion was 
“all adults 19+ years”, and articles in “all languages”. A total 
of 15 randomized, controlled clinical trials evaluating the 
efficacy and safety of first-generation long-acting injectables 
were retrieved. One of these retrieved articles was written in 
a non-English language.12 An English version of the abstract 
and the Italian version of the full manuscript were available, 
the results of which were interpreted by a native speaker. 
No articles meeting the selection criteria above were found for 
the following, and hence were excluded from further analysis: 
clopenthixol decanoate, flupenthixol decanoate, pipothiazine 
palmitate, fluspirilene, and perphenazine enanthate. No placebo-
controlled relapse prevention studies for long-acting injectable 
olanzapine and long-acting injectable risperidone were found in 
the literature search. Additionally, the search did not retrieve any 
studies of first-generation long-acting injectable antipsychotics 
for the acute treatment of patients with schizophrenia. A search 
of published Cochrane reviews also did not provide additional 
studies meeting the inclusion criteria.13–15
For paliperidone palmitate, a search within the internal 
company database (“literature management and documenta-
tion”) was performed using the search terms, “double-blind”, 
“randomized”, “human”, and “intramuscular”, with the 
indication “schizophrenia”. The internal database contains 
all published abstracts, posters, and manuscripts for company 
products and is not publicly accessible, although many of the 
documents may be found through other external searches. 
Four studies of acute treatment and one of maintenance treat-
ment for schizophrenia were identified.
selected studies
We then narrowed the selected studies to those that included 
a placebo control, because comparisons between treatments 
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  comparator, eg, placebo. A common comparator is necessary 
to allow for characterization of the efficacy and safety of the 
treatments of interest with reference to the same comparator 
across studies. These types of comparisons are indirect 
in nature and distinct from observations in a randomized 
controlled trial that include direct head-to-head comparisons 
of the treatments of interest. Furthermore, because calculations 
of NNT and NNH require binary endpoints, we included only 
those publications that had clinical outcomes of interest with 
binary endpoints that were common among at least two of the 
published studies, and provided enough details to be able to 
assess them. Studies with continuous variables for efficacy 
and safety measures that could not be converted to binary 
endpoints were not included.   Accordingly, of the 16 retrieved 
studies for maintenance treatment, only seven (six for first-
generation long-acting injectables, and one for paliperidone 
palmitate) fully met the inclusion criteria of being placebo-
controlled and having binary endpoints for clinical outcomes 
of interest. Of these, six studies had time to relapse or relapse 
rate as a clinical efficacy endpoint.12,16,18–21 The only study 
retrieved for bromperidol decanoate did not assess efficacy 
using time to relapse or relapse rate, and hence was included 
only for safety evaluations using NNH.22
Of the four acute treatment studies with paliperidone 
palmitate that were initially identified, three used a lower 
dose-loading regimen than that currently approved by the 
US Food and Drug Administration, so were excluded,23–25 
leaving one acute treatment study for the main analysis.17 
These three studies utilized an older dosing regimen that 
led to considerably lower initial plasma concentrations of 
paliperidone. A subsequent sensitivity analysis including 
these three studies with alternative dosing regimens was 
conducted and yielded similar results (Table 1).
Selection of efficacy and safety endpoints 
for comparison
From the identified studies, as expected, not all outcomes 
were reported uniformly in the published manuscripts. Thus, 
prevention of relapse was compared between paliperidone 
palmitate, fluphenazine decanoate, and haloperidol decanoate 
(the only bromperidol decanoate study included did not assess 
prevention of relapse). The NNT for response to treatment 
was calculated from the Pandina et al17 study for paliperidone 
palmitate. Thus, the efficacy parameters chosen were “response” 
(based upon $30% reduction in the Positive and Negative 
Symptoms Scale [PANSS] total score from baseline at the last 
postbaseline assessment) in the acute treatment study17 and 
“relapse” (as derived from data on “time to relapse” or “relapse 
rate”) in the maintenance treatment studies.12,16,18–21
The six safety parameters chosen across the studies were: (1) 
incidences of reported adverse event rates of akathisia, tremor, 
tardive dyskinesia, or weight gain, as well as (2) the proportion 
of patients who used anticholinergic medications (which is an 
indirect measure of clinically relevant extrapyramidal symptom-
related effects, and the proportion of patients who had emergence 
of a “positive” Abnormal Involuntary Movement Scale (AIMS) 
total score as reported in each of the publications. Accordingly, 
the incidence of tardive dyskinesia was compared between 
paliperidone palmitate, fluphenazine decanoate, and haloperidol 
decanoate. Incidences of anticholinergic medication use, and 
AIMS positive score were compared between paliperidone 
palmitate and fluphenazine decanoate, and treatment-emergent 
tremor, akathisia, and weight gain were compared between 
paliperidone palmitate and bromperidol decanoate.
Calculation of NNT, NNH, and LHH
NNT and NNH were calculated as the reciprocal of the absolute 
difference in event rates (Table 2). LHH was calculated based 
on the method described by Straus.9 Survival studies with an 
Table 1 Sensitivity analysis for number needed to harm and number 
needed to treat for acute symptom studies for paliperidone palmitate 
that used an earlier initiation regimen
Clinical outcome  
NNT or NNH  
(95% CI)
aGopal  
et al25
bNasrallah  
et al24
cKramer  
et al23
response 9 (5, 64) 8 (5, 26) 5 (4, 12)
Akathisia  78 (24, -37) -322 (46, -21) -87 (42, -15)
Tremor -210 (29, -18) 100 (34, -38) -57 (65, -14)
Tardive dyskinesia 252 (46, -42) ∞ ∞
Use of  
anticholinergics
33 (10, -20) -81 (27, -13) 12 (7, 545)
AiMs positive  
score
22 (8, -22) -108 (16, -11) -37 (13, -7)
Weight gain 36 (18, -299) 28 (17, 313) 2739 (31, -19)
Notes: ∞ indicates confidence interval includes infinity; initial dose on days 1 and 8: 
a50, 100, 150 mg eq; b25, 50, 100 mg eq; c50, 100 mg eq.
Abbreviations:  AiMs,  Abnormal  involuntary  Movement  scale;  NNT,  number 
needed to treat; NNH, number needed to harm; CI, confidence interval.
Table 2 Formulae used to calculate number needed to treat, 
number  needed  to  harm,  and  likelihood  of  being  helped  or 
harmed
Measure of effect Formula
NNT 1/ARR = 1/St - Sc
NNh 1/ARI = 1/St - Sc
Lhh ARR/ARI = NNH/NNT
Abbreviations: ARR, absolute risk reduction; ARI, absolute risk increase; St, event 
rate in treatment group; Sc, event rate in control group; NNT, number needed to 
treat; NNH, number needed to harm; LHH, likelihood of being helped or harmed.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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endpoint of time to relapse require an estimate of the survival 
probability at fixed time points to support calculation of NNT. 
Because older studies lacked information on the corresponding 
survival probability, hazard ratio or number at risk were used. 
For comparison, we calculated the confidence interval (CI) for 
NNT at distinct time points (6 and 12 months) for the paliperi-
done palmitate study. The CIs of NNT to prevent relapse in 
other studies with various fixed durations (6–48 months) were 
calculated according to the method described by Altman and 
Andersen.26 CIs for NNT for treatment response (ie, $30% 
reduction from baseline in PANSS total score) and CI of NNH 
for the selected safety measures were constructed using the 
Wilson score method using a program written in SAS 9.1 (SAS 
Institute Inc, Cary, NC).27–29
All comparisons performed in this analysis were con-
ducted by comparing the event rate in the medication-of-
interest group with the placebo group event rate in the 
selected studies. Negative values for NNT or NNH imply 
that the treatment of interest is more likely to result in harm 
than benefit. For example, a negative NNT in this analysis 
indicates that a patient assigned to the medication of interest 
is more likely to experience relapse than a patient assigned to 
placebo. Similarly, a negative NNH indicates that a patient 
assigned to placebo has a lower risk for the adverse event 
than a patient assigned to the medication of interest. Infinity 
values for NNT or NNH indicate that an infinite number of 
patients would be required to show any benefit or harm. If 
the 95% CI for NNT or NNH includes infinity, the finding 
is considered statistically nonsignificant.
Results
study characteristics
Across the selected maintenance studies of first-generation 
long-acting injectables and paliperidone palmitate, the patient 
stabilization period before randomization, if applicable, 
varied between two months and two years. Additionally, 
the follow-up time varied significantly between the studies 
(range 6–48 months), and the relapse rates varied across the 
placebo-treated groups (range 30%–71%).
Across the selected randomized controlled survival 
studies, the crude relapse rates in the long-acting injectable-
treated groups were similar (range 10%–19%, Table 3). The 
NNT to prevent relapse relative to placebo ranged between 
two and five for paliperidone palmitate, fluphenazine decano-
ate, and haloperidol decanoate (Table 4 and Figure 1). NNT 
for clinical response reflected the established efficacy of 
paliperidone palmitate relative to placebo for the primary 
efficacy measure (ie, change from baseline in PANSS total 
score, Table 4). For bromperidol decanoate, no relevant effi-
cacy data were available to calculate an NNT.
Across the selected maintenance (relapse prevention) 
studies, the NNH for anticholinergic medication use (30 to 42 
[paliperidone palmitate] versus -5 to 5 [fluphenazine decano-
ate]), tardive dyskinesia (infinity [paliperidone palmitate] 
Table 3 Key features of studies included in NNT and NNH analysis 
Sample 
size
Dosing Study duration Incidence of relapse
(n) Range Dosing  
interval
Stabilization  
period
Double-blind  
period
Active treatment  
group, n/total, (%)
Placebo group 
n/total, (%)
Paliperidone palmitate 
hough et al16 
Pandina et al17
410 
652
25–100 mg eqa 
25–150 mg eqb
4 weeks 
4 weeks
33 weeks  
NA
Variable range 
13 weeks
36/205 (18%) 
NA
97/203 (48%) 
NA
haloperidol decanoate 
eklund and Forsman18 56 60 mg 4 weeks 15 weeks 48 weeks 2/20 (10%) 16/23 (70%)
Bromperidol decanoate 
smeraldi et al22 20 150 mg Monthly NA 6 months Not mentioned Not mentioned
Fluphenazine decanoate 
hirsch et al19 
Jolley et al20 
Odejide and Aderounmu21 
Dotti et al12
(48 weeks)
81 
54 
53 
20
12–25 mgc 
NAd 
50 mg 
25–50 mg
2–4 weeks 
4 weeks 
4–8 weeks 
monthly
8 weeks 
2 months 
2 years 
6 months
15 months 
48 months 
12 months 
9 months
6/36 (17%) 
3/25 (12%) 
5/21 (19%) 
1/10 (10%)
27/38 (71%) 
12/24 (50%) 
15/27 (56%) 
3/10 (30%)
Notes: aDoses are given monthly and ranges are expressed in terms of mg eq (234 mg paliperidone palmitate = 150 mg eq of paliperidone; 156 mg paliperidone palmitate = 
100 mg eq of paliperidone; 78 mg paliperidone palmitate = 50 mg eq of paliperidone); bInitial dose on day 1 with 150 mg eq, followed by either 150, 100 or 25 mg eq. cMinimum 
dose 25 mg/month or 12.5 mg/biweekly. No upper limit for dose specified; dDose range not specified. Mean dose of fluphenazine decanoate 25.6 mg. Oral haloperidol   
(5–10 mg/d) allowed for up to 2 weeks to treat prodromal symptoms.
Abbreviation: NA, not available (not reported in primary manuscript).Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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the adverse event of interest than a patient assigned to the 
medication under study. For the comparison with haloperidol 
decanoate, the NNH for tardive dyskinesia favored pali-
peridone palmitate (infinity [paliperidone palmitate] versus 1 
[haloperidol decanoate]). An infinite NNH means there is no 
difference in rates for the unfavorable outcome between the 
two interventions being compared (ie, placebo and medica-
tion of interest). However, no other relevant safety data were 
available to calculate a NNH for haloperidol   decanoate for 
the other assessed parameters, ie, akathisia, tremor, anticho-
linergic medication, AIMS positive score, or weight gain. 
For the comparison with bromperidol decanoate, the NNH 
favored paliperidone palmitate for akathisia (205 versus 10 
[bromperidol decanoate]) and tremor (69 to 207 versus -5 
[bromperidol decanoate]). The NNH for weight gain with 
paliperidone palmitate ranged from 16 to 19 versus 10 (bro-
mperidol decanoate), again favoring paliperidone palmitate. 
Weight gain was not reported as an adverse event in any of 
the haloperidol decanoate and fluphenazine decanoate studies 
selected. NNH results for the acute paliperidone palmitate 
study are provided in Table 5.
The LHH for selected parameters from maintenance 
studies of paliperidone palmitate or fluphenazine decanoate 
relative to placebo ranged between 3 and infinity across 
the measures of harm, and favored treatment with 
paliperidone palmitate (Table 6). The LHH for haloperidol 
decanoate and bromperidol decanoate could not be analyzed 
because the selected publications did not report the relevant 
safety or efficacy data necessary to calculate the parameters 
relative to placebo.
Discussion
In the absence of head-to-head comparative data from clinical 
studies of first- and second-generation long-acting injectable 
antipsychotics, calculation of NNT, NNH, and LHH across 
distinct studies can be useful to convey relative benefits, 
risks, and the ratio of benefit to risk between treatments to 
patients, payers, caregivers, and clinicians.9,30 One of the 
important benefits of using likelihood ratios is the ease of 
calculation and the ability to compare similar events across 
different studies. LHH analysis is most meaningful when 
LHH is compared across studies with similar objectives and 
design characteristics. NNT and NNH also provide clinically 
relevant information. Kraemer and Kupfer suggest that an 
NNT of 2.3, 3.6, and 8.9 corresponds to a Cohen’s “d” of 
0.8, 0.5, and 0.2, respectively, representing effect sizes that 
are “large”, “medium”, and “small”.6 A single-digit NNT 
usually denotes a favorable outcome that will commonly be 
Table 4 Number needed to treat for selected clinical outcomes
Relapse prevention 
(NNT 95% CI)
Response 
(NNT 95% CI)
Paliperidone palmitate 
Long-term, hough et al16  
(six months) 
Long-term, hough et al16 
(12 months) 
Acute, Pandina et al17  
(13 weeks)
3 (2.3, 4.2) 
2 (1.5, 2.7) 
–
NA 
NA 
6 (4, 10)
haloperidol decanoate 
eklund and Forsman18  
(48 weeks)
2 (1.0, 4.4)* NA
Bromperidol decanoate 
smeraldi et al22 (6 months) NA NA
Fluphenazine decanoate 
hirsch et al19 (nine months) 
Jolley et al20 (two years) 
Odejide and Aderounmu21  
(12 months) 
Dotti et al12 (48 weeks)
2 (1.2, 3.2)* 
3 (1.4, 18.7)* 
3 (1.5, 21.1)* 
5 (1.8, -6)
NA 
NA 
NA 
NA
Notes:  NNT  calculated  relative  to  placebo  within  each  study.  95%  confidence 
intervals  computed  based  upon  Wilson  scores;  *Statistically  significant  results; 
response rates calculated based on 30% reduction in PANss score. Negative bound 
for upper 95% confidence interval indicates a disjoint encompassing both the positive 
value to positive infinity, and the negative value to negative infinity. 
Abbreviations:  NA,  not  available  (not  reported  in  primary  manuscript); 
CI,  confidence  interval;  NNT,  number  needed  to  treat;  PANSS,  Positive  and 
Negative symptoms scale.
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Figure 1 NNT point estimates and 95% confidence intervals for prevention of 
relapse. 
Notes: Point estimate for NNT is noted with a circle. Whiskers represent upper 
and lower bounds of the 95% CI. Disjointed CI indicates that it starts from negative 
infinity and ends at positive infinity. 
Abbreviations:  ci,  confidence  interval;  NNT,  number  needed  to  treat;  PP, 
paliperidone  palmitate;  HD,  haloperidol  decanoate;  FD,  fluphenazine  decanoate; 
BD, bromperidol decanoate.
versus 7 [fluphenazine decanoate]), and emergence of AIMS 
positive score (-33 to -28 [paliperidone palmitate] versus 
13 [fluphenazine decanoate]) indicated a lower incidence of 
treatment-emergent movement disorders with paliperidone 
palmitate (Table 5). A negative NNH means that a patient 
assigned to the comparator (placebo) has a lower risk for Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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encountered in daily clinical practice. However, a high NNH 
indicates that a medication is relatively innocuous in terms 
of the outcome of interest, whereas a small NNH indicates 
that the agent is associated with a relatively higher risk of an 
adverse event. Thus, a long-acting injectable antipsychotic 
with a favorable benefit-to-risk ratio is one with a low NNT 
and high NNH relative to placebo or another long-acting 
injectable.10 A negative NNT means that patients may be 
more likely to experience a harmful outcome (relapse) by the 
treatment. Similarly, a negative NNH means that a favorable 
effect of treatment on safety parameters cannot be excluded. 
In addition, it should be noted that when the 95% CI for either 
the NNT or NNH contains a negative bound, it indicates that 
the interval includes infinity, which implies that an infinite 
number of patients would be required to show any benefit, or 
harm, with 95% confidence, and hence denotes undetermined 
clinical relevance.
In the current analysis, the NNT for clinical response 
during acute treatment confirmed the established efficacy of 
paliperidone palmitate relative to placebo for the predefined 
Table 5 Number needed to harm for selected clinical outcomes
Akathisia 
(NNH 95% CI)
Tremor 
(NNH 95% CI)
Tardive 
dyskinesia 
(NNH 95% CI)
Use of 
anticholinergics 
(NNH 95% CI)
AIMS  
positive score 
(NNH 95% CI)
Weight gain 
(NNH 95% CI)
Paliperidone palmitate 
Long-term, hough et al16  
(six months) 
Long-term, hough et al16  
(12 months) 
Acute, Pandina et al17  
(13 weeks)
 
205 (37, -71) 
 
205 (37, -71) 
 
-102 (45, -18)
 
207 (33, -54) 
 
69 (23, -93) 
 
-83 (118, -20)
 
∞ 
 
∞ 
 
∞
 
42 (13, -35) 
 
30 (11, -49) 
 
-90 (23, -13)
 
-28 (26, -9) 
 
-33 (27, -10) 
 
53 (13, -19)
 
19 (11, 50) 
 
16 (9, 40) 
 
10,004 (59, -31)
haloperidol decanoate 
eklund and Forsman18  
(48 weeks)
 
NA
 
NA
 
1
 
NA
 
NA
 
NA
Bromperidol decanoate 
smeraldi et al22 (6 months)
 
10 (2, -4)
 
-5 (6, -2)
 
NA
 
NA
 
NA
 
10 (2, -5)
Fluphenazine decanoate 
hirsch et al19 (nine months) 
Jolley et al20 (two years) 
Odejide and Aderounmu21  
(12 months) 
Dotti et al12 (48 weeks)
 
NA 
NA 
NA 
 
NA
 
NA 
NA 
NA 
 
NA
 
NA 
7 (-10, 3) 
NA 
 
NA
 
5 (3, 96) 
NA 
-5 (20, -2) 
 
NA
 
NA 
NA 
13 (4, -12) 
 
NA
 
NA 
NA 
NA 
 
NA
Notes: NNH calculated relative to placebo within each study. 95% confidence intervals computed based upon Wilson scores; ∞ = confidence interval includes infinity (due 
to zero incidence in denominator); Negative numbers for NNH indicate that placebo was more likely to harm. Negative bound for upper 95% confidence interval indicates 
a disjoint encompassing both the positive value extending to positive infinity, and the negative value extending to negative infinity. 
Abbreviations: NA, not available (not reported in primary manuscript); AIMS, Abnormal Involuntary Movement Scale; NNH, number needed to harm; CI, confidence 
interval.
Table 6 Likelihood of being helped or harmed by paliperidone palmitate or fluphenazine decanoate relative to placebo
Comparison of interest Benefit NNT Harm NNH LHH
PPa/placebo Prevent relapse 2.0 Anticholinergic medication use 30.0 15.1
FDb/placebo Prevent relapse 2.0 Anticholinergic medication use 5.0 3.0
PPa/placebo Prevent relapse 2.0 Tardive dyskinesia ∞ ∞
FDc/placebo Prevent relapse 3.0 Tardive dyskinesia 7.0 3.0
PPa/placebo Prevent relapse 2.0 emergent AiMs positive score -32.2 NA
FDd/placebo Prevent relapse 3.0 emergent AiMs positive score 13.0 5.0
PPe/placebo clinical responsef 6.0 Anticholinergic medication use -89.3 NA
PPe/placebo clinical responsef 6.0 emergent AiMs positive score 52.2 10.0
PPe/placebo clinical responsef 6.0 emergent extrapyramidal symptoms 488.0 89.0
Notes: NNT and NNh calculated relative to placebo, eg, [1/(% LAi – % placebo)]. Lhh calculated as [NNh/NNT]. Negative NNT indicates that the placebo was more 
beneficial than the LAI. Positive NNT indicates that the LAI was more beneficial than the placebo. Negative NNH indicates that the placebo was more harmful than the LAI. 
NA = negative Lhh not interpretable. ∞ = infinity. Publications used for comparisons of interest: ahough et al;16 bhirsch et al;19 cJolley et al;20 dOdejide and Aderounmu;21 
ePandina et al;17 fclinical response (PANss improvement ($30%).
Abbreviations: PANss, Positive and Negative symptoms scale, NNT, number needed to treat; NNh, number needed to harm; AiMs, Abnormal involuntary Movement 
scale; LAi, long-acting injectable.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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primary efficacy measure. This result is to be interpreted 
with caution, considering that the search criteria retrieved 
only one relevant study for paliperidone palmitate that 
evaluated the product’s efficacy and safety for acute treat-
ment of patients with schizophrenia and no studies for any 
of the first-generation long-acting injectables. The NNTs to 
prevent relapse relative to placebo were similar between pali-
peridone palmitate, fluphenazine decanoate, and haloperidol 
decanoate, while no relevant efficacy data were available for 
bromperidol decanoate. Overall, the NNH favored paliperi-
done palmitate over fluphenazine decanoate for the assessed 
safety measures. As a result, the paired calculations of LHH 
for benefit with regard to relapse, as well as risk for each 
of the distinct measures of harm, also favored paliperidone 
palmitate over fluphenazine decanoate. Similarly, the NNHs 
as measures of harm for anticholinergic medication use, onset 
of tardive dyskinesia, and emergent AIMS positive score, 
favored paliperidone palmitate over fluphenazine decanoate. 
Because we did not obtain efficacy data to calculate NNT for 
relapse prevention during maintenance treatment, or data to 
calculate NNH for all the selected safety parameters for the 
first-generation antipsychotic long-acting injectables evalu-
ated, a comparison of LHH between paliperidone palmitate 
and bromperidol decanoate or haloperidol decanoate was 
not possible.
Many of the previous reports comparing first- and 
second-generation antipsychotics only compared the oral 
formulations.31–33 Similar comparative data on first- versus 
second-generation long-acting injectables, especially data 
from head-to-head comparisons, which can provide the 
strongest evidence, are lacking. However, our findings are 
consistent with a previous meta-analysis for NNT and NNH 
that showed fewer extrapyramidal side effects with second-
generation oral antipsychotics than their first-generation 
oral antipsychotics.34 Thus, the results from these analyses 
provide important information, especially for the comparison 
of specific extrapyramidal symptom-related adverse events 
and tardive dyskinesia between the newly approved long-
acting injectable, paliperidone palmitate, and the selected 
first-generation long-acting injectables.
The favorable results from LHH analyses for paliperidone 
palmitate are especially important, because tardive dyskinesia 
is one of the main adverse effects of concern with the use of 
first-generation antipsychotics in the treatment of schizophre-
nia.5 The prevalence of tardive dyskinesia has been estimated 
to be between 24%–56% in chronic antipsychotic users,35 
13%–36% in hospitalized adult patients,36 and 25%–30% 
among elderly patients treated with first-generation oral 
antipsychotics.4 Several studies have consistently reported 
a higher risk of treatment-limiting tardive dyskinesia with 
the first-generation oral antipsychotics than with the second-
generation oral antipsychotics.4,5,37 Consistent with these 
reports for oral formulations, a recent comparative review 
suggests that first-generation long-acting injectables are also 
associated with an increased incidence of acute and chronic 
movement disorders compared with the second-generation 
long-acting injectable, risperidone.38 In recently published 
paliperidone palmitate trials, there were no reports of tardive 
dyskinesia in the short-term trials (n = 1805),17,23–25 and only 
one report in the longer-term trials (n = 1010).16,39,40
However, second-generation oral antipsychotics are generally 
considered to be associated with an increased incidence of 
metabolic adverse events and weight gain.41–43 Metabolic adverse 
events for the selected first-generation long-acting injectables 
and paliperidone palmitate could not be compared in this 
analysis due to lack of adequate data from the selected first-
generation long-acting injectable studies. However, weight gain 
in long-term treatment, reported as an adverse event, could be 
compared, and favored paliperidone palmitate over bromperidol 
decanoate (NNH 16–19 for paliperidone palmitate versus 10 
for bromperidol decanoate). Previous short-term paliperidone 
palmitate studies23–25 (up to 13 weeks), a recent long-term 
paliperidone palmitate study,39 and a recent comparative review 
that included paliperidone palmitate studies up to one year in 
duration44 report low mean changes from baseline in body weight 
(-1.0 kg to 2.6 kg). For body weight increases from baseline of at 
least 7% versus placebo, an NNH of 12 and 13 for paliperidone 
palmitate studies was reported.44
Limitations of the current analysis include lack of more 
current data on first-generation long-acting injectables 
to compare with paliperidone palmitate, incomplete data 
reported in the selected studies for comparison, lack of 
data on other second-generation long-acting injectables (eg, 
risperidone), differences in study design among the selected 
studies (eg, immediate randomization to distinct treatment 
groups or randomized withdrawal after initial stabilization), 
different definitions of relapse, small sample size of older 
studies, variable length of follow-up, and different propor-
tions of patients pretreated with medications to minimize 
adverse events (eg, anti-extrapyramidal symptom medica-
tion). At the time of this analysis, long-acting injectable 
risperidone was also considered for comparison, but was 
later excluded because the relevant studies did not meet the 
inclusion criteria for the analysis. Furthermore, because of 
the lack of any published studies with conventional long-
acting injectables in the acute setting, it was not possible to Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
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compare NNT for treatment response. NNT or NNH is not 
“an all-inclusive measure of benefit or harm”, but provides 
clinicians with a means of weighing benefits versus risks 
of the medications in the class when determining the most 
appropriate course of treatment for an individual patient. 
While it is difficult to interpret a potential net benefit or harm 
based on multiple NNTs or NNHs for individual parameters, 
this method constitutes a valuable addition to the decision-
making tool kit for patient care. Thus, availability of NNTs or 
NNHs for various efficacy and safety parameters may facili-
tate more individualized decision-making in the management 
of patients with distinct baseline characteristics.
Because the risks and benefits documented on the basis 
of aggregate clinical trial data vary between the antipsy-
chotic long-acting injectables, it is important for prescribers 
to individualize treatment decisions based upon the bal-
ance of opposing benefits and risks for their patients with 
a distinct clinical presentation and a specific set of risk 
factors. In the present analysis, paliperidone palmitate was 
generally found to have a similar NNT and a more favorable 
NNH compared with selected first-generation long-acting 
injectables for maintenance treatment in patients with 
schizophrenia.
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